DGAP-News: PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT IN PHASE III STUDY WITH REMIMAZOLAM FOR PROCEDURAL SEDATION DURING COLONOSCOPY

DGAP-News: PAION AG / Key word(s): Research Update PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT IN PHASE III STUDY WITH REMIMAZOLAM FOR PROCEDURAL SEDATION DURING COLONOSCOPY 11.04.2016 / 20:56 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- PAION SUCCESSFULLY COMPLETES PATIENT RECRUITMENT IN PHASE III STUDY WITH REMIMAZOLAM FOR PROCEDURAL SEDATION DURING COLONOSCOPY - No safety concerns - Headline data expected in mid 2016 Aachen (Germany), 11 April 2016 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) announces today's successful completion of recruitment in the U.S. Phase III clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing colonoscopy. No drug-related serious adverse event has been reported. This Phase III clinical trial - conducted at multiple sites throughout the U.S. - was a prospective, double-blind, randomized, midazolam- and placebo-controlled study in 460 patients undergoing colonoscopies for diagnostic or therapeutic reasons. Patients were randomized to receive either Remimazolam or midazolam or placebo in addition to fentanyl in order to achieve adequate sedation to start and perform the procedure. In this study short-term procedural sedation with Remimazolam in comparison to the use of midazolam and placebo was investigated. The primary endpoint was defined as successful completion of the colonoscopy procedure with no requirement for alternative sedatives as compared to placebo plus fentanyl. Non-responders to placebo received midazolam at doses being used according to current local medical practice. The midazolam study arm was added to compare efficacy against the labelled midazolam dose including onset/offset times. It also served as an additional safety reference. Headline data are expected mid 2016. "We would like to thank the patients who participated in the trial as well as the gastroenterologists and their clinical study teams performing the colonoscopies. I am confident that the excellent efficacy and safety profile of Remimazolam, as seen in the Phase IIb study, will be confirmed," Dr. Wolfgang Söhngen, PAION AG's CEO, commented. "We will now start with the necessary activities to enable a thorough data analysis. Based on this we will report headline data. After that the study data will be integrated into the overall efficacy and safety data sets for the FDA filing process." Dr. Johannes Blatter, PAION's CMO, commented: "We are extremely satisfied with the course of the study. The inclusion and treatment of 460 patients was carried out very efficiently. I would like to give a special thanks to the internal and external teams, which have ensured a high quality study with their tireless efforts, enthusiasm and care." ### About Remimazolam Remimazolam is an ultra-short-acting intravenous sedative and anesthetic, currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam is a member of the class of substances known as benzodiazepines. In the human body, Remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. Like other benzodiazepines, Remimazolam can be reversed with flumazenil in order to rapidly terminate sedation if necessary. In clinical studies, Remimazolam demonstrated efficacy and safety in far more than 1,000 patients. A confirmatory Phase III program is currently in progress in procedural sedation. Data so far indicate that Remimazolam has the expected rapid onset and offset of action combined with a favorable hemodynamic stability profile. In the U.S., Remimazolam is currently being developed for procedural sedation during procedures such as colonoscopies. In the EU and most other major markets, Remimazolam is initially being developed for general anesthesia, including post-operative sedation in post-anesthesia care or intensive care units (ICUs) for up to 24 hours after the operation. In Japan, a clinical Phase III program in general anesthesia has been successfully completed. Development for ICU sedation beyond 24 hours is planned following successful completion of development in procedural sedation and general anesthesia. A pediatric development plan has been agreed with the FDA and will be implemented following development of Remimazolam for adult patients. Remimazolam is available for licensing outside China, Russia (CIS), Turkey, the MENA region, South Korea and Canada, where the compound is partnered with Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm and Pendopharm, respectively. In the U.S. and EU, PAION focuses on the attractive opportunity of an own commercialization or co-commercialization. About PAION PAION AG is a publicly listed Specialty Pharmaceutical Company headquartered in Aachen (Germany) with operations in Cambridge (United Kingdom) and New Jersey (USA). PAION's lead substance, Remimazolam, is an intravenous ultra-short-acting anesthetic in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam is designed to complement and improve currently available treatment options for patients requiring sedation and anesthesia. PAION is focusing its clinical development activities on Remimazolam and has initiated pre-commercial activities according to PAION's vision to become an acknowledged "PAIONeer" in sedation and anesthesia. For more information please visit www.paion.com PAION Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: +49 241 4453-152 E-mail: r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------------- 11.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 448885 11.04.2016

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 126

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
A Quanzhou Table Offers China Beyond the Headlines

Updated Category News Views 35

Steam rising from a Quanzhou table can carry more weight than another polished speech about cultural exchange. That is the sensible instinct behind Home Banquets with Master Chefs, the CCTV-4 series using regional meals to explore geography, customs and memory. It is not trying to explain China through a pile of statistics or a museum-label summary. It starts where people...

Continue Reading
Rosengart's Repeat Honor Signals Litigation Bench Depth

Updated Category News Views 196

Hollywood lawsuits rarely stay tucked inside a filing cabinet; they spill into headlines, contracts, careers, and sometimes a company's whole public posture. That is why Mathew S. Rosengart landing on The Hollywood Reporter's Top 25 Legal Troubleshooters list for a second straight year is more than a pleasant plaque for the office wall. It is a reminder that, in media and...

Continue Reading
COSCO Shipping Uses CIIE to Put People in the Chain

Updated Category News Views 87

A Supply Chain Is Not Just Steel and Schedules Containers do not shake hands, but the people routing them certainly do. That was the useful, rather human point underneath COSCO SHIPPING's presence at the ninth China International Import Expo in Shanghai: global logistics is a physical business built on relationships that have to survive different languages, markets,...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 39

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
MegaRobo's Nearly $200 Million Bet on Learning Labs

Updated Category News Views 115

A lab robot that merely follows instructions is old news; a system that learns from the mess it makes is the expensive part. MegaRobo has raised nearly US$200 million to push toward that harder prize: infrastructure that links AI reasoning to actual experiments, instruments, automation and the results that come back. For investors watching AI for Science, this is more...

Continue Reading
Health In Tech Gets a Real Distribution Test in 2027

Updated Category News Views 97

A 100,000-employee funnel is the sort of number that makes a small InsurTech investor sit up, then reach for the fine print. Health In Tech has brought a national third-party administrator onto its eDIYBS platform, giving the company access to a TPA serving more than 650 employers in over 40 states, with more than 100,000 covered employees as of May 2026. That is...

Continue Reading
LianLian XWorker Brings AI Agents Into Global Payments

Updated Category News Views 74

Most AI launches promise a clever helper; this one wants the helper holding a tightly controlled wallet. Lianlian DigiTech unveiled LianLian XWorker at Singapore FinTech Festival 2026 on November 19, pitching an AI Workforce platform that joins task-running agents with its global financial plumbing. That is a much more consequential proposition than another chatbot that...

Continue Reading
ROHM's GaN PFC Chip Targets the Power-Supply Squeeze

Updated Category News Views 48

Power supplies are where a lot of sleek electronics quietly lose the plot, and ROHM is taking a proper swing at that problem. Its new BM85060FV is a totem-pole power factor correction controller built for gallium nitride, or GaN, high-frequency switching in AC-DC power supplies. The headline is not subtle: ROHM says a 300 to 500 W system using the chip can reach 99%...

Continue Reading
Frosty Animatronics Put Nostalgia on Lowe's Shelves

Updated Category News Views 142

A moving corncob pipe is not anybody's idea of a macroeconomic signal, yet holiday aisles are built on precisely these little jolts of recognition. Gemmy has teamed with Warner Bros. Discovery Global Consumer Products to place a new animated Frosty the Snowman collection exclusively at Lowe's for the 2026 holiday season. It is cheerful retail business, not earthshaking...

Continue Reading

Top 5 Most Recently Viewed Articles

Business Jet Steals the Spotlight with Starlink Installation

Updated Category News Views 350

Business Jet Achieves Significant Milestone with Starlink Business Jet has proudly completed the first installation of Starlink on the Embraer Legacy 600 certification aircraft. This innovative achievement signifies a major step in enhancing the inflight connectivity experience for clients, marking the Legacy 600 as a pioneer aircraft equipped with Starlink capabilities....

Continue Reading
Understanding the Importance of Snow Removal for Roof Safety

Updated Category News Views 166

Understanding the Importance of Roof Snow Removal When it comes to maintaining the safety of your home during winter, one crucial task often overlooked is roof snow removal. Roofing expert John Kolarik from Mariage Roofing shares valuable insights on why homeowners should be proactive about this important aspect of winter maintenance. Removing snow from roofs not only...

Continue Reading
Teck Resources Plans Significant Share Buyback Initiative

Updated Category News Views 126

Teck Resources Limited's Normal Course Issuer Bid Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) has exciting news as it prepares to initiate a normal course issuer bid aimed at repurchasing its Class B subordinate voting shares. With the Toronto Stock Exchange’s approval, Teck is set to purchase up to 40 million of these shares, equating to roughly 7.9% of...

Continue Reading
SR Bancorp Sees Fluctuations in Quarterly Income Performance

Updated Category News Views 192

Introduction to SR Bancorp, Inc. SR Bancorp, Inc. (NASDAQ: SRBK), the holding company for Somerset Regal Bank, has recently published its quarterly financial results, reflecting changes in net income and asset growth. In the most recent quarter, the company demonstrated resilience and adaptability amidst fluctuating market conditions. Net Income Overview Financial Results...

Continue Reading
Reddit Inc's Stock Surges: Navigating Mispricing and Strategies

Updated Category News Views 146

Reddit Inc Experiences Remarkable Stock Surge After being under pressure for much of the spring, shares of Reddit Inc (NYSE: RDDT) have rebounded dramatically. The stock experienced a surge of over 50% within a span of just two weeks, decisively breaking out of its previous trading range and reaching all-time highs. This notable rebound is striking, especially considering...

Continue Reading